Retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: Impact of 2007 American society of clinical oncology/college of American pathologists criteria

Archives of Pathology and Laboratory Medicine

Volumn 138, Issue 2, 2014, Pages 213-219

  Schalper, Kurt A ^a,b   Kumar, Sudha ^a   Hui, Pei ^a   Rimm, David L ^a   Gershkovich, Peter ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSIDAD DEL DESARROLLO   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; BREAST TUMOR; CANCER GRADING; CARCINOMA; COHORT ANALYSIS; COMPARATIVE STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAMMARY GLAND; MEDICAL SOCIETY; METABOLISM; MIDDLE AGED; PATHOLOGY; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; TUMOR INVASION; UNITED STATES; UNIVERSITY HOSPITAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; COHORT STUDIES; CONNECTICUT; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MAMMARY GLANDS, HUMAN; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PRACTICE GUIDELINES AS TOPIC; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SOCIETIES, MEDICAL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84893687974     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2012-0617-OA     Document Type: Article

References (27)

1. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-182.
2. Andrulis IL, Bull SB, Blackstein ME, et al. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer: Toronto Breast Cancer Study Group. J Clin Oncol. 1998;16(4):1340-1349.
3. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118-145.
4. Shah SS, Ketterling RP, Goetz MP, et al. Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer. Hum Pathol. 2010;41(1):103-106.
5. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-792.
6. Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29(25):3366-3373.
7. Shah S, Chen B. Testing for HER2 in breast cancer: a continuing evolution. Patholog Res Int. 2011:903202.
8. Perez EA, Dueck AC, McCullough AE, et al. Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. J Natl Cancer Inst. 2011;104(2):159-162.
9. Atkinson R, Mollerup J, Laenkholm AV, et al. Effects of the change in cutoff values for human epidermal growth factor receptor 2 status by immunohistochemistry and fluorescence in situ hybridization: a study comparing conventional brightfield microscopy, image analysis-assisted microscopy, and interobserver variation. Arch Pathol Lab Med. 2011;135(8):1010-1016.
10. Grimm EE, Schmidt RA, Swanson PE, et al. Achieving 95% crossmethodological concordance in HER2 testing: causes and implications of discordant cases. Am J Clin Pathol. 2010;134(2):284-292.
11. Lal P, Salazar PA, Hudis CA, et al. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a singleinstitution experience of 2,279 cases and comparison of dual-color and singlecolor scoring. Am J Clin Pathol. 2004;121(5):631-636.
12. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 2004;5(1):63-69.
13. Ahmed SS, Iqbal J, Thike AA, et al. HER2/neu revisited: quality and interpretive issues. J Clin Pathol. 2011;64(2):120-124.
14. Vergara-Lluri ME, Moatamed NA, Hong E, et al. High concordance between HercepTest immunohistochemistry and ERBB2 fluorescence in situ hybridization before and after implementation of American Society of Clinical Oncology/College of American Pathology 2007 guidelines. Mod Pathol. 2012; 25(10):1326-1332.
15. Gown AM, Goldstein LC, Barry TS, et al. High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system. Mod Pathol. 2008;21(10):1271-1277.
16. Varshney D, Zhou YY, Geller SA, et al. Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay. Am J Clin Pathol. 2004;121(1):70-77.
17. Yildiz-Aktas IZ, Dabbs DJ, Cooper KL, et al. The effect of 96-hour formalin fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma. Am J Clin Pathol. 2012;137(5):691-698.
18. Moatamed NA, Nanjangud G, Pucci R, et al. Effect of ischemic time, fixation time, and fixative type on HER2/neu immunohistochemical and fluorescence in situ hybridization results in breast cancer. Am J Clin Pathol. 2011;136(5):754-761.
19. Selvarajan S, Bay BH, Choo A, et al. Effect of fixation period on HER2/neu gene amplification detected by fluorescence in situ hybridization in invasive breast carcinoma. J Histochem Cytochem. 2002;50(12):1693-1696.
20. Yildiz-Aktas IZ, Dabbs DJ, Bhargava R. The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma. Mod Pathol. 2012;25(8): 1098-1105.
21. Khoury T, Sait S, Hwang H, et al. Delay to formalin fixation effect on breast biomarkers. Mod Pathol. 2009;22(11):1457-1467.
22. Portier BP, Wang Z, Downs-Kelly E, et al. Delay to formalin fixation 'cold ischemia time': effect on ERBB2 detection by in-situ hybridization and immunohistochemistry. Mod Pathol. 2012;26(1):1-9.
23. Roche PC, Ingle JN. Increased HER2 with US Food and Drug Administration-approved antibody. J Clin Oncol. 1999;17(1):434.
24. Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissuebased detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000;18(21):3651-3664.
25. Vranic S, Teruya B, Repertinger S, et al. Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17. Cancer. 2011;117(1):48-53.
26. Hyun CL, Lee HE, Kim KS, et al. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer. J Clin Pathol. 2008;61(3):317-321.
27. Middleton LP, Price KM, Puig P, et al. Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases. Arch Pathol Lab Med. 2009;133(5):775-780.